PRESS RELEASE published on 07/01/2024 at 12:30, 2 months 18 days ago NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections NanoViricides, Inc. elaborates on its lead broad-spectrum antiviral drug candidate NV-387, poised to revolutionize viral disease treatment. Plans include Phase II studies for RSV and market expansion NV-387 NanoViricides Inc. Antiviral Drug Viral Diseases Phase II Studies
BRIEF published on 06/24/2024 at 12:05, 2 months 25 days ago NV-387 de NanoViricides : une avancée potentielle contre la grippe aviaire H5N1 NanoViricides NV-387 H5N1 La Grippe Aviaire Antiviral
BRIEF published on 06/24/2024 at 12:05, 2 months 25 days ago NanoViricides’ NV-387: A Potential Breakthrough Against Bird Flu H5N1 NanoViricides NV-387 H5N1 Antiviral Bird Flu
PRESS RELEASE published on 06/24/2024 at 12:00, 2 months 25 days ago A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides NanoViricides, Inc. comments on the potential of ultra-broad-spectrum antiviral NV-387 against bird flu H5N1 viruses. The company's drug candidate shows promising results in lethal animal model studies NV-387 Clinical Trials NanoViricides Inc. Antiviral Drug Bird Flu H5N1
BRIEF published on 06/20/2024 at 12:35, 2 months 29 days ago L'antiviral NV-387 de NanoViricides présente une protection pulmonaire prometteuse dans les modèles de grippe A NanoViricides NV-387 Grippe A Antiviral Protection Des Poumons
BRIEF published on 06/20/2024 at 12:35, 2 months 29 days ago NanoViricides' Antiviral NV-387 Shows Promising Lung Protection in Influenza A Models NanoViricides NV-387 Influenza A Antiviral Lung Protection
PRESS RELEASE published on 06/20/2024 at 12:30, 2 months 29 days ago A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model NanoViricides, Inc. reports positive results of NV-387 in protecting lungs from damage in influenza virus infection. NV-387 treatment showed reduced lung infiltration, cell death, mucus load, and increased survival NV-387 NanoViricides Inc Antiviral Nanomedicines Lung Protection Influenza Treatment
BRIEF published on 06/11/2024 at 12:35, 3 months 8 days ago Le NV-387 présente des propriétés antivirales prometteuses avec une concentration sanguine soutenue NanoViricides NV-387 Essais Cliniques Antiviral À Large Spectre Concentration Sanguine Plate
BRIEF published on 06/11/2024 at 12:35, 3 months 8 days ago NV-387 Shows Promising Antiviral Properties with Sustained Blood Concentration NanoViricides NV-387 Clinical Trials Broad-spectrum Antiviral Flat Blood Concentration
PRESS RELEASE published on 06/11/2024 at 12:30, 3 months 8 days ago Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect NanoViricides, Inc. reports positive results of broad-spectrum antiviral drug NV-387 in animal models, showing sustained antiviral effect with extended flat blood concentration profile upon oral administration NV-387 Broad-spectrum Antiviral Drug NanoViricides Inc Animal Models Oral Administration
Published on 09/20/2024 at 02:00, 10 minutes ago Academy of Math and Science Celebrates Hispanic Heritage Month
Published on 09/19/2024 at 23:15, 2 hours 55 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 3 hours 10 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 23:00, 3 hours 10 minutes ago Cerrado Files NI 43-101 Preliminary Economic Assessment Technical Report and Mineral Resource Estimate for The Minera Don Nicolas Mine in Santa Cruz, Argentina
Published on 09/19/2024 at 21:09, 5 hours 1 minute ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 7 hours 26 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 8 hours 7 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 8 hours 18 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 8 hours 18 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 8 hours 25 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 8 hours 25 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 8 hours 25 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)